$TORC News
Last published 5y ago
- 5y agoTORCA Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly - NCT04668352ClinicalTrials.govPercentage of subjects with clinically symptomatic respiratory illness
- 6y agoTORCA Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults - NCT04584710ClinicalTrials.govTo determine the length of time from date of receipt of a positive SARS-CoV2 test result to date of first dose of study drug in asymptomatic adults age ≥ 65 years, To determine the feasibility of using an eDiary to assess study drug compliance in the study drug population, To determine the feasibility of using an eDiary to assess COVID-19 symptoms in the study population, (and 5 more...)
- 6y agoTORCAdicet Announces Completion of Merger with resTORbioGlobeNewswire- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology - -Trading to Commence on September 16, 2020 on The Nasdaq Global Market Under Ticker Symbol “ACET”- ...
- 6y agoTORCresTORbio Provides Corporate Update and Reports Second Quarter 2020 Financial ResultsGlobeNewswireBOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
- 6y agoTORCresTORbio and TrialSpark collaborate to investigate RTB-101 for COVID-19 on the Project Covalence platformPR NewswireTrialSpark, a tech-enabled drug development partner committed to improving the speed, quality, and innovation of clinical trials, today announced a...
- 6y agoTORCresTORbio Announces an Award from the National Institute on Aging to Fund a Pilot Study of RTB101 as COVID-19 Prophylaxis in Older AdultsGlobeNewswireBOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- resTORbio resTORbio, Inc. (Nasdaq: TORC) today announced the award from the National Institute on Aging to fund a randomized, double-blind,...
- 6y agoTORCresTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19 in Nursing Home ResidentsGlobeNewswireBOSTON, May 28, 2020 (GLOBE NEWSWIRE) -- resTORbio (Nasdaq: TORC) today announced the initiation of a randomized, double-blind, placebo-controlled trial of RTB101, an investigational...
- 6y agoTORCSTMLKLXEPTLAMoore Kuehn Encourages TORC, STML, KLXE, and PTLA Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
- 6y agoSDGRTTPHTORCSchrödinger Strengthens Board of Directors with Appointments of Jeffrey Chodakewitz, M.D., and Gary GinsbergBusiness WireNEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced the appointments of Jeffrey A. Chodakewitz, M.D., and Gary Ginsberg to its Board of Directors. Dr. Chodakewitz is a veteran in the biopharmaceutical industry who previously held leadership roles at Vertex Pha ...
- 6y agoTORCresTORbio to Host its 2020 Annual Shareholder Meeting Virtually on June 3, 2020GlobeNewswireBOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC) today announced that due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being...
- 6y agoTORCresTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy TechnologyGlobeNewswireCombined Company to Focus on Adicet’s Technology and Continue Operations as “Adicet Bio” Adicet’s lead asset ADI-001 is an allogeneic gamma delta T cell therapy expressing a chimeric antigen receptor...
- 6y agoTORCresTORbio Announces Delay of its Ongoing Phase 1b/2a trial of RTB101 in Patients with Parkinson’s Disease Due to COVID-19 Level 4 Alert in New ZealandGlobeNewswireBOSTON, April 03, 2020 (GLOBE NEWSWIRE) -- resTORbio (Nasdaq: TORC) today announced that it will postpone enrollment in the fifth cohort of its ongoing Phase 1b/2a trial of RTB101, an orally...
- 6y agoTORCresTORbio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate UpdateGlobeNewswireBOSTON, March 12, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
- 6y agoTORCresTORbio Announces Interim Results for Phase 1b/2a Trial of RTB101 in Patients with Parkinson’s Disease and Provides Corporate UpdateGlobeNewswire-- Interim data from three cohorts in the Phase 1b/2a study demonstrate that RTB101 is well tolerated, crosses the blood brain barrier, and reaches concentrations in cerebrospinal fluid observed in...
- 6y agoTORCPimco's Below Consensus Forecast for January U.S. Payrolls ReportBloomberg
- 6y agoTORCresTORbio to Present at Upcoming Investor ConferencesGlobeNewswireBOSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
- 6y agoTORCresTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary EndpointGlobeNewswire-- Company stops further development of clinically symptomatic respiratory illness indication but continues development of RTB101 in other aging-related diseases, including Parkinson’s disease -- --...
- 7y agoTORCresTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019GlobeNewswireBOSTON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
- 7y agoTORCresTORbio to Present at the 2019 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewswireBOSTON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
- 7y agoTORCresTORbio to Present Findings on Investigational TORC1 Inhibitor RTB101 in Late-Breaking Session at IDWeek™ 2019GlobeNewswireBOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...